# A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

> **NCT03270176** · PHASE1 · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 54 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Neoplasms

## Interventions

- **DRUG:** Debio 1143
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03270176
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-10
- **Primary completion:** 2022-03-22
- **Final completion:** 2022-03-22
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03270176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03270176, "A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03270176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*